Match!
Benedetta Rambaldi
University of Brescia
ImmunologyGraft-versus-host diseaseBone marrowTransplantationMedicine
17Publications
5H-index
68Citations
What is this?
Publications 19
Newest
#1Benedetta Rambaldi (UNIPV: University of Pavia)
#1Benedetta RambaldiH-Index: 5
Last. Edwin P. AlyeaH-Index: 72
view all 15 authors...
Haploidentical hematopoietic cell transplantation (haplo-HCT) with post-transplant cyclophosphamide (PTCy) as graft versus host disease (GVHD) prophylaxis is frequently used for patients who do not have HLA-identical donors. However, the effect of PTCy on immune reconstitution (IR) has not been studied extensively in large prospective cohorts, despite a high incidence of early viral infections. We quantified IR in 60 patients after haplo-HCT with PTCy, mycophenolate mofetil and tacrolimus (TAC) ...
Source
#1Susanne H. C. Baumeister (Harvard University)H-Index: 8
Last. Rizwan RomeeH-Index: 18
view all 4 authors...
Hematopoietic stem cell transplantation from a haploidentical donor is increasingly used and has become a standard donor option for patients lacking an appropriately matched sibling or unrelated donor. Historically, prohibitive immunological barriers resulting from the high degree of HLA-mismatch included graft-versus-host disease (GVHD) and graft failure. These were overcome with increasingly sophisticated strategies to manipulate the sensitive balance between donor and recipient immune cells. ...
Source
Source
#1Michele Malagola (University of Brescia)H-Index: 21
#2Nicola Polverelli (University of Brescia)H-Index: 14
Last. Domenico Russo (University of Brescia)H-Index: 34
view all 14 authors...
We present a case of a patient with a three-month history of peripheral blood cytopenia without a confirmed diagnosis of myelodysplastic syndrome, who developed a favourable-risk acute myeloid leukemia (AML), according to the European Leukemia Net (ELN) criteria. The patient achieved a complete remission with incomplete platelet recovery (CRi) after induction. The patient achieved the morphological CR after the first consolidation and completed the first-line treatment with a syngeneic stem cell...
Source
#1Alessandro TurraH-Index: 5
#2Nicola PolverelliH-Index: 14
Last. Domenico RussoH-Index: 34
view all 19 authors...
Source
Source
#1Simona Bernardi (University of Brescia)H-Index: 7
#2Camilla Zanaglio (University of Brescia)H-Index: 2
Last. Domenico Russo (University of Brescia)H-Index: 34
view all 13 authors...
Introduction In AML and MDS cases, the genetic lesions inherited or acquired by the hematopoietic stem cells are considered as starting events. Familial AML and MDS, recently recognized in the revised WHO classification (2016) provide a useful model for investigation of predisposing genetic mutations. Genetic analysis of several pure familial leukemia pedigrees led to the discovery of well defined syndromes associated with inherited de novo mutations on germline DNA. Growing clinical awareness a...
Source
#1Michele MalagolaH-Index: 21
#2Jacopo PeccatoriH-Index: 24
Last. Domenico Russo (University of Brescia)H-Index: 34
view all 24 authors...
Source
#1Nicola Polverelli (University of Brescia)H-Index: 14
#2Michele Malagola (University of Brescia)H-Index: 21
Last. Domenico Russo (University of Brescia)H-Index: 34
view all 18 authors...
1 CitationsSource
#1Alice Pievani (University of Milano-Bicocca)H-Index: 6
#2Ilaria M. Michelozzi (University of Milano-Bicocca)H-Index: 2
Last. Marta Serafini (University of Milano-Bicocca)H-Index: 14
view all 8 authors...
There is still an unmet need for xenotransplantation models that efficiently recapitulate normal and malignant human hematopoiesis. Indeed, there are a number of strategies to generate humanized mice and specific protocols, including techniques to optimize the cytokine environment of recipient mice and drug alternatives or complementary to the standard conditioning regimens, that can be significantly modulated. Unfortunately, the high costs related to the use of sophisticated mouse models may li...
Source
12